Table 1.

Characteristics of included studies

Source	Design	Duration	Participants	Mean age	Intervention and control	Outcome
Kuca et al.[19]	Randomized, double-blind, placebo controlled	17 months	n: 2,231	Intervention group	Intervention group	Primary Efficacy outcomes:
				Lasmiditan 100 mg - 42.2	Lasmiditan 100 mg, Lasmiditan 200 mg	Headache pain free at 2 h
				Lasmiditan 200 mg - 41.4		Secondary efficacy outcomes:
				Control group	Control group	MBS free at 2 h, 24 h and 48 h.
				Placebo - 42.4	Placebo	Headache relief at 2 h.
						Safety outcomes:
						Treatment-emergent adverse events (TEAEs) after the first dose
Goadsby et al.[20]	Prospective, randomized, double-blind, placebo controlled, multi-Centre phase 3 study	14 months	n: 3005	Intervention group	Intervention group	Primary efficacy outcomes:
				Lasmiditan 50 mg- 42.8	Lasmiditan 50 mg	Headache pain free at 2 h, MBS free at 2 h
				Lasmiditan 100 mg - 43.4	Lasmiditan 100 mg	Secondary efficacy outcomes:
				Lasmiditan 200 mg - 41.8	Lasmiditan 200 mg	Sustained pain freedom at 24 h & 48 h and Headache relief at 2 h.
				Control group	Control group
				Placebo - 42.6	Placebo	Safety outcomes:
						Treatment-emergent adverse events (TEAEs) after the first dose

n: Total number of participants; MBS: Most Bothersome Symptoms